Jade Biosciences, Inc. (JBIO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Jade Biosciences, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 13 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 19.80 $ — 65% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 144.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 3
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.28 | -2.28 – -2.28 | 0 | – | 1 |
| 12/31/2027 | -2.28 | -2.28 – -2.28 | 0 | 0.1% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.66 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -6.56 | – | 0 | – | – | -11 | -11 |
| 2025: Q1 | -3.04 | – | 0 | – | – | -19 | -19 |
| 2025: Q2 | -1.13 | – | 0 | – | – | -37 | -37 |
| 2025: Q3 | -0.64 | – | 0 | – | – | -22 | -22 |
| 2025: Q4 | -0.65 | – | 0 | – | – | -34 | -34 |
| 2026: Q1 | -0.70 | – | 0 | – | – | -24 | -24 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2020 | – | -9 | -10 | -13.78 | -8 | 3 | 5 |
| 2021 | – | -23 | -23 | -32.92 | -27 | 172 | 175 |
| 2022 | – | -53 | -52 | -73.67 | -39 | 127 | 135 |
| 2023 | – | -81 | -76 | -100.38 | -57 | 109 | 127 |
| 2024 | – | -75 | -70 | -85.26 | -71 | 76 | 80 |
| 2025 | 0 | -114 | -127 | -4.06 | -95 | 333 | 350 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Jade Biosciences, Inc. ist ein Biotechnologieunternehmen, das Therapien für Entzündungs- und Immunindikationen bei Patienten mit Autoimmunerkrankungen entwickelt.
| Employees | 55 |
|---|---|
| Headquarters | Waltham, MA |
| Address | Building 23, 02453 Waltham, United States |
| Phone | 781 312 3013 |
| Website | jadebiosciences.com |
| IPO Date | 30. Jun 2021 |
| ISIN | US0080642061 |
| Stock Split | 1:35 on 04/29/2025 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Tom Frohlich | President, CEO & Director | 1976 |
| Bradford D. Dahms Ph.D. | CFO & Treasurer | 1989 |
| Andrew James King BVMS, D.V.M., Ph.D. | President of Research & Development | 1980 |
| Elizabeth Balta J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Lori Stewart | Senior Vice President of People | – |
| Jonathan Quick | Senior Vice President of Finance | – |
| Valerie Fauvelle | Senior Vice President of Regulatory & Quality | – |
| Amy Sullivan | Senior Vice President of Development Operations | – |
| Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy | – |
| Edward R. Conner M.D. | Chief Medical Officer | 1973 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.